Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.54 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492630 | 0.91 | HCRTR1 (0.54) | FKBP1AL3MBTL1MAPK1TSHRSMN1; SMN2 | |
| SCHEMBL5497980 | 0.90 | FKBP1A (0.58) | FKBP1AITGB1ITGA4ITGA2ITGA5 | |
| SCHEMBL5494189 | 0.90 | FKBP1A (0.67) | FKBP1AITGB1ITGA4ITGA2L3MBTL1 | |
| SCHEMBL5487316 | 0.85 | FKBP1A (0.61) | FKBP1AITGB1ITGA4ITGA2FOLH1 | |
| SCHEMBL5690973 | 0.84 | ITGB1 (0.65) | FKBP1AITGB1ITGA4ITGA2ITGA5 | |
| SCHEMBL5496177 | 0.83 | FKBP1A (0.56) | FKBP1AITGB1ITGA4ITGA2L3MBTL1 | |
| SCHEMBL5491587 | 0.83 | FKBP1A (0.54) | FKBP1AITGB1ITGA4ITGA2L3MBTL1 | |
| SCHEMBL5495223 | 0.83 | FKBP1A (0.54) | FKBP1AITGB1ITGA4ITGA2L3MBTL1 | |
| SCHEMBL6712279 | 0.83 | ITGB1 (0.55) | FKBP1AITGB1ITGA4ITGA2ITGA5 | |
| SCHEMBL6708383 | 0.83 | ITGB1 (0.63) | FKBP1AITGB1ITGA4ITGA2ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | claimed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | claimed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7288526-B2 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, IL4I1 | FKBP1A 4722/4885ITGB1 169/4885ITGA4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.